Skip to content

About
Team
Portfolio
News
Contact

Category Archives: Immunwork

News

Immunwork

Five Questions with Immunwork

Posted on 2016-09-232021-02-07 by maxproadmin

Posted in Immunwork

News

Portfolio Company News

Acepodia
ACT Genomics
Advaxis
Anbogen
Apollomics
Arthrosi
EirGenix
Foresee Pharmaceuticals
GenScript
HEC Pharm
Immunwork
JHL
SyneuRx
Original BioMedicals
Polaris Pharmaceuticals

Recent News

Apollomics Appoints Matthew Plunkett, Ph.D. as Chief Financial Officer
Acepodia Announces FDA Clearance of Investigational New Drug Application for ACE2016, a First-in-Class Allogeneic Anti-EGFR Cell Therapy
Anbogen Secures $12.5 Million USD in Series A Funding, Advancing Precision Oncology Drug Development
Apollomics Completes Enrollment in Phase 3 Bridging Study of Uproleselan in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia
Apollomics Presents Interim Data from Two Ongoing Phase 2 Clinical Trials with Vebreltinib in NSCLC Patients with MetExon14 Skipping Mutation

Taipei

+886 2 7713 7952

5F-4, No.89, Songren Rd., Xinyi Dist., Taipei City, Taiwan 11073

Shanghai

+86 18411036556

Room503, Jiangbang Department, No. 368 Hongguan Rd, HongKou Dist., Shanghai, China 200086

North Hollywood

+1 949 308 5609

5250 Lankershim Blvd., Suite 500, North Hollywood, CA 91601

Arcadia

+1 626 242 4429

440 E Huntington Dr Suite 300, Arcadia, CA 91006

Irvine

+1 626 242 4429

Room 651,17901 Von Karman Avenue
Suite 600, Irvine, CA, 92614, USA

COPYRIGHT © 2021 MAXPRO ALL RIGHTS RESERVED.

Copyright 2024 © UX Themes

About
Team
Portfolio
News
Contact